SlideShare a Scribd company logo
1 of 20
The Discovery of PPAR Ligands Using Parallel Synthesis
Lead Discovery Strategies Low High High Low Knowledge Base Compound Diversity random screening targeted screening database mining focused libraries small pools combinatorial mixtures discrete compounds
Peroxisome Proliferator-Activated Receptors (PPARs) ,[object Object],[object Object],1 liver, kidney, heart PPAR  DNA Ligand 468 1 broadly expressed PPAR  86 70 440 1 adipose, spleen PPAR  83 68 475
PPARs and Metabolic Diseases Subtype PPAR  PPAR  PPAR  Function Triglycerides HDL Glucose ??? Disease CV Risk Factors Type 2 Diabetes ??? Goal: Rapid identification of potent, subtype selective  PPAR ligands
PPAR Profile of Common Fibrates
PPAR Targeted Library Design Z pharmacophore link X Y Diverse monomers  Diverse monomers  pharmacophore link X Y
Retrosynthesis
Resin Loading 25mg of resin = 5mg product (MW=500)
DIC HOBT BH 3 •THF R 2 1 NCO R 2 2 NCO R 2 3 NCO R 2 4 NCO R 2 5 NCO R 2 6 NCO R 2 7 NCO R 2 8 NCO R 1 1 CO 2 H R 1 3 CO 2 H R 1 5 CO 2 H R 1 7 CO 2 H  R 1 9 CO 2 H R 1 2 CO 2 H R 1 4 CO 2 H R 1 6 CO 2 H R 1 8 CO 2 H  R 1 10 CO 2 H 10% TFA Parallel Synthesis of PPAR Ligands Pip/DMF
PPAR Screening Data A B C D E F G H X  (Acids) Y  (Isocyanates) plate 1 plate 2 PPAR  PPAR  PPAR  a b c d e f g h i j k l m n o p q r s t % activation 75-100 50-75 25-50 0-25
PPAR   Deconvolution X Y Pharmacophore PPAR   EC 50  (  M) GW 2433 e e f k n n B G B G B G — — — — — — — — 6.3 2.0 — — 1.9 0.16 6.3 0.25 7.9 1.6
PPAR   Radioligand hPPAR  K d  = 20 nM Bound (nM) 3 H-GW 2433 (nM) GW 2433 Total Specific Non-specific
Thioisobutyric Acids (TIBA) ,[object Object],[object Object],[object Object]
Alternative Synthesis
Resin Loading 0.63 mmole/g  100% Loading
R 1 8 OH  R 1 10 OH R 1 6 OH R 1 5 OH R 1 4 OH R 1 3 OH R 1 1 OH R 1 2 OH DIAD PPh 3 HSCH 2 COOH R 2 1 NCO R 2 2 NCO R 2 3 NCO R 2 4 NCO R 2 5 NCO R 2 6 NCO R 2 7 NCO R 2 8 NCO R 1 7 OH  R 1 9 OH 10% TFA Parallel Synthesis of PPAR Ligands
PPAR Screening Data PPAR  PPAR  GW 9578 PPAR  % activation 75-100 50-75 25-50 0-25 X  (Alcohols) Y  (Isocyanates)
PPAR Profile of GW 9578 GW 9578 Fenofibric Acid 300 14 mPPAR EC 50  (  M) 0.005 18 1.5 250    Sel  GW 9578 Fenofibric Acid 1.4 >300 20 10 hPPAR EC 50  (  M) 0.05 30 1 300    Sel  GW 9578 Fenofibric Acid 2.6 >300
Summary ,[object Object],[object Object],[object Object],[object Object]
PPAR Acknowledgements Medicinal Chemistry Peter Brown Adam Fivush Gordon Hodgson Kevin Hurley Dan Sternbach Bill Stuart Nick Tomkinson Tim Willson Tommaso Messeri Radiochemistry Itzela Correa Shimoga Prakash Structural Chemistry Paul Charifson Tom Consler Bruce Wisely Metabolic Diseases Mike Lewis Deborah Winegar William Oliver Joan Wilson Other Collaborators Jim Chapman  (Univ. South Carolina) Molecular Endocrinology Steve Kliewer Jürgen Lehmann David Morris Kelli Plunket Tracey Smith-Oliver Laura Wade Molecular Biochemistry Steve Blanchard Lisa Miller Derek Parks Lisa Leesnitzer Analytical Chemistry Doug Minick

More Related Content

Similar to Brown San Diego99

Poster: Functional analysis of essential hypothetical proteins of Staphylococ...
Poster: Functional analysis of essential hypothetical proteins of Staphylococ...Poster: Functional analysis of essential hypothetical proteins of Staphylococ...
Poster: Functional analysis of essential hypothetical proteins of Staphylococ...Pranavathiyani G
 
PARP-1 Inhibitors In Oncology
PARP-1 Inhibitors In OncologyPARP-1 Inhibitors In Oncology
PARP-1 Inhibitors In OncologyGregory J. Wells
 
PPAR alpha poster
PPAR alpha posterPPAR alpha poster
PPAR alpha posterEric Cobb
 
The discovery of AZD4547
The discovery of AZD4547The discovery of AZD4547
The discovery of AZD4547David Andrews
 
Perspective on QSAR modeling of transport
Perspective on QSAR modeling of transportPerspective on QSAR modeling of transport
Perspective on QSAR modeling of transportSean Ekins
 
Stability indicating method development and validation for the simultaneous e...
Stability indicating method development and validation for the simultaneous e...Stability indicating method development and validation for the simultaneous e...
Stability indicating method development and validation for the simultaneous e...pharmaindexing
 
Htos Presentation
Htos PresentationHtos Presentation
Htos Presentationbenmz101
 
EUGM 2014 - Ádám Andor Kelemen (Hungarian Academy of Sciences): Physicochemic...
EUGM 2014 - Ádám Andor Kelemen (Hungarian Academy of Sciences): Physicochemic...EUGM 2014 - Ádám Andor Kelemen (Hungarian Academy of Sciences): Physicochemic...
EUGM 2014 - Ádám Andor Kelemen (Hungarian Academy of Sciences): Physicochemic...ChemAxon
 
Simplified receptor based pharmacophore approach to retrieve potent ptp lar i...
Simplified receptor based pharmacophore approach to retrieve potent ptp lar i...Simplified receptor based pharmacophore approach to retrieve potent ptp lar i...
Simplified receptor based pharmacophore approach to retrieve potent ptp lar i...rajmaha9
 
Discriminating Facts from Artefacts in the Secreted Ly-6 Protein Family
Discriminating Facts from Artefacts in the Secreted Ly-6 Protein FamilyDiscriminating Facts from Artefacts in the Secreted Ly-6 Protein Family
Discriminating Facts from Artefacts in the Secreted Ly-6 Protein FamilyChris Southan
 
PPAR alpha final research paper
PPAR alpha final research paperPPAR alpha final research paper
PPAR alpha final research paperEric Cobb
 
Varda Rotter - Weizmann Institute of Science.
Varda Rotter - Weizmann Institute of Science.Varda Rotter - Weizmann Institute of Science.
Varda Rotter - Weizmann Institute of Science.Fundación Ramón Areces
 
Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1
Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1
Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1Attività scientifica
 
Accelrys UGM slides 2011
Accelrys UGM slides 2011Accelrys UGM slides 2011
Accelrys UGM slides 2011Sean Ekins
 
Ddtdpcr array poster
Ddtdpcr array posterDdtdpcr array poster
Ddtdpcr array posterElsa von Licy
 
The 5' terminal uracil of let-7a is critical for the recruitment of mRNA to A...
The 5' terminal uracil of let-7a is critical for the recruitment of mRNA to A...The 5' terminal uracil of let-7a is critical for the recruitment of mRNA to A...
The 5' terminal uracil of let-7a is critical for the recruitment of mRNA to A...David W. Salzman
 

Similar to Brown San Diego99 (20)

Poster: Functional analysis of essential hypothetical proteins of Staphylococ...
Poster: Functional analysis of essential hypothetical proteins of Staphylococ...Poster: Functional analysis of essential hypothetical proteins of Staphylococ...
Poster: Functional analysis of essential hypothetical proteins of Staphylococ...
 
PARP-1 Inhibitors In Oncology
PARP-1 Inhibitors In OncologyPARP-1 Inhibitors In Oncology
PARP-1 Inhibitors In Oncology
 
PPAR alpha poster
PPAR alpha posterPPAR alpha poster
PPAR alpha poster
 
The discovery of AZD4547
The discovery of AZD4547The discovery of AZD4547
The discovery of AZD4547
 
Sot2007
Sot2007Sot2007
Sot2007
 
Perspective on QSAR modeling of transport
Perspective on QSAR modeling of transportPerspective on QSAR modeling of transport
Perspective on QSAR modeling of transport
 
Stability indicating method development and validation for the simultaneous e...
Stability indicating method development and validation for the simultaneous e...Stability indicating method development and validation for the simultaneous e...
Stability indicating method development and validation for the simultaneous e...
 
Htos Presentation
Htos PresentationHtos Presentation
Htos Presentation
 
EUGM 2014 - Ádám Andor Kelemen (Hungarian Academy of Sciences): Physicochemic...
EUGM 2014 - Ádám Andor Kelemen (Hungarian Academy of Sciences): Physicochemic...EUGM 2014 - Ádám Andor Kelemen (Hungarian Academy of Sciences): Physicochemic...
EUGM 2014 - Ádám Andor Kelemen (Hungarian Academy of Sciences): Physicochemic...
 
Simplified receptor based pharmacophore approach to retrieve potent ptp lar i...
Simplified receptor based pharmacophore approach to retrieve potent ptp lar i...Simplified receptor based pharmacophore approach to retrieve potent ptp lar i...
Simplified receptor based pharmacophore approach to retrieve potent ptp lar i...
 
Discriminating Facts from Artefacts in the Secreted Ly-6 Protein Family
Discriminating Facts from Artefacts in the Secreted Ly-6 Protein FamilyDiscriminating Facts from Artefacts in the Secreted Ly-6 Protein Family
Discriminating Facts from Artefacts in the Secreted Ly-6 Protein Family
 
JOURNAL CLUB PRESENTATION (20L81S0704-PA )
JOURNAL CLUB PRESENTATION (20L81S0704-PA )JOURNAL CLUB PRESENTATION (20L81S0704-PA )
JOURNAL CLUB PRESENTATION (20L81S0704-PA )
 
PARP Poly ADP Ribose
PARP Poly ADP RibosePARP Poly ADP Ribose
PARP Poly ADP Ribose
 
PPAR alpha final research paper
PPAR alpha final research paperPPAR alpha final research paper
PPAR alpha final research paper
 
Kieran_ccpNMR
Kieran_ccpNMRKieran_ccpNMR
Kieran_ccpNMR
 
Varda Rotter - Weizmann Institute of Science.
Varda Rotter - Weizmann Institute of Science.Varda Rotter - Weizmann Institute of Science.
Varda Rotter - Weizmann Institute of Science.
 
Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1
Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1
Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1
 
Accelrys UGM slides 2011
Accelrys UGM slides 2011Accelrys UGM slides 2011
Accelrys UGM slides 2011
 
Ddtdpcr array poster
Ddtdpcr array posterDdtdpcr array poster
Ddtdpcr array poster
 
The 5' terminal uracil of let-7a is critical for the recruitment of mRNA to A...
The 5' terminal uracil of let-7a is critical for the recruitment of mRNA to A...The 5' terminal uracil of let-7a is critical for the recruitment of mRNA to A...
The 5' terminal uracil of let-7a is critical for the recruitment of mRNA to A...
 

Recently uploaded

IESVE for Early Stage Design and Planning
IESVE for Early Stage Design and PlanningIESVE for Early Stage Design and Planning
IESVE for Early Stage Design and PlanningIES VE
 
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...FIDO Alliance
 
Strategic AI Integration in Engineering Teams
Strategic AI Integration in Engineering TeamsStrategic AI Integration in Engineering Teams
Strategic AI Integration in Engineering TeamsUXDXConf
 
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdfThe Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdfFIDO Alliance
 
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...FIDO Alliance
 
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdfIntroduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdfFIDO Alliance
 
AI presentation and introduction - Retrieval Augmented Generation RAG 101
AI presentation and introduction - Retrieval Augmented Generation RAG 101AI presentation and introduction - Retrieval Augmented Generation RAG 101
AI presentation and introduction - Retrieval Augmented Generation RAG 101vincent683379
 
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdfLinux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdfFIDO Alliance
 
What's New in Teams Calling, Meetings and Devices April 2024
What's New in Teams Calling, Meetings and Devices April 2024What's New in Teams Calling, Meetings and Devices April 2024
What's New in Teams Calling, Meetings and Devices April 2024Stephanie Beckett
 
TEST BANK For, Information Technology Project Management 9th Edition Kathy Sc...
TEST BANK For, Information Technology Project Management 9th Edition Kathy Sc...TEST BANK For, Information Technology Project Management 9th Edition Kathy Sc...
TEST BANK For, Information Technology Project Management 9th Edition Kathy Sc...marcuskenyatta275
 
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya HalderCustom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya HalderCzechDreamin
 
Extensible Python: Robustness through Addition - PyCon 2024
Extensible Python: Robustness through Addition - PyCon 2024Extensible Python: Robustness through Addition - PyCon 2024
Extensible Python: Robustness through Addition - PyCon 2024Patrick Viafore
 
Optimizing NoSQL Performance Through Observability
Optimizing NoSQL Performance Through ObservabilityOptimizing NoSQL Performance Through Observability
Optimizing NoSQL Performance Through ObservabilityScyllaDB
 
Syngulon - Selection technology May 2024.pdf
Syngulon - Selection technology May 2024.pdfSyngulon - Selection technology May 2024.pdf
Syngulon - Selection technology May 2024.pdfSyngulon
 
IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024IoTAnalytics
 
Free and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
Free and Effective: Making Flows Publicly Accessible, Yumi IbrahimzadeFree and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
Free and Effective: Making Flows Publicly Accessible, Yumi IbrahimzadeCzechDreamin
 
Salesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
Salesforce Adoption – Metrics, Methods, and Motivation, Antone KomSalesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
Salesforce Adoption – Metrics, Methods, and Motivation, Antone KomCzechDreamin
 
Google I/O Extended 2024 Warsaw
Google I/O Extended 2024 WarsawGoogle I/O Extended 2024 Warsaw
Google I/O Extended 2024 WarsawGDSC PJATK
 
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...CzechDreamin
 
How we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdfHow we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdfSrushith Repakula
 

Recently uploaded (20)

IESVE for Early Stage Design and Planning
IESVE for Early Stage Design and PlanningIESVE for Early Stage Design and Planning
IESVE for Early Stage Design and Planning
 
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
 
Strategic AI Integration in Engineering Teams
Strategic AI Integration in Engineering TeamsStrategic AI Integration in Engineering Teams
Strategic AI Integration in Engineering Teams
 
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdfThe Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
 
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
 
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdfIntroduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
 
AI presentation and introduction - Retrieval Augmented Generation RAG 101
AI presentation and introduction - Retrieval Augmented Generation RAG 101AI presentation and introduction - Retrieval Augmented Generation RAG 101
AI presentation and introduction - Retrieval Augmented Generation RAG 101
 
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdfLinux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
 
What's New in Teams Calling, Meetings and Devices April 2024
What's New in Teams Calling, Meetings and Devices April 2024What's New in Teams Calling, Meetings and Devices April 2024
What's New in Teams Calling, Meetings and Devices April 2024
 
TEST BANK For, Information Technology Project Management 9th Edition Kathy Sc...
TEST BANK For, Information Technology Project Management 9th Edition Kathy Sc...TEST BANK For, Information Technology Project Management 9th Edition Kathy Sc...
TEST BANK For, Information Technology Project Management 9th Edition Kathy Sc...
 
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya HalderCustom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
 
Extensible Python: Robustness through Addition - PyCon 2024
Extensible Python: Robustness through Addition - PyCon 2024Extensible Python: Robustness through Addition - PyCon 2024
Extensible Python: Robustness through Addition - PyCon 2024
 
Optimizing NoSQL Performance Through Observability
Optimizing NoSQL Performance Through ObservabilityOptimizing NoSQL Performance Through Observability
Optimizing NoSQL Performance Through Observability
 
Syngulon - Selection technology May 2024.pdf
Syngulon - Selection technology May 2024.pdfSyngulon - Selection technology May 2024.pdf
Syngulon - Selection technology May 2024.pdf
 
IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024
 
Free and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
Free and Effective: Making Flows Publicly Accessible, Yumi IbrahimzadeFree and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
Free and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
 
Salesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
Salesforce Adoption – Metrics, Methods, and Motivation, Antone KomSalesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
Salesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
 
Google I/O Extended 2024 Warsaw
Google I/O Extended 2024 WarsawGoogle I/O Extended 2024 Warsaw
Google I/O Extended 2024 Warsaw
 
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
 
How we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdfHow we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdf
 

Brown San Diego99

  • 1. The Discovery of PPAR Ligands Using Parallel Synthesis
  • 2. Lead Discovery Strategies Low High High Low Knowledge Base Compound Diversity random screening targeted screening database mining focused libraries small pools combinatorial mixtures discrete compounds
  • 3.
  • 4. PPARs and Metabolic Diseases Subtype PPAR  PPAR  PPAR  Function Triglycerides HDL Glucose ??? Disease CV Risk Factors Type 2 Diabetes ??? Goal: Rapid identification of potent, subtype selective PPAR ligands
  • 5. PPAR Profile of Common Fibrates
  • 6. PPAR Targeted Library Design Z pharmacophore link X Y Diverse monomers Diverse monomers pharmacophore link X Y
  • 8. Resin Loading 25mg of resin = 5mg product (MW=500)
  • 9. DIC HOBT BH 3 •THF R 2 1 NCO R 2 2 NCO R 2 3 NCO R 2 4 NCO R 2 5 NCO R 2 6 NCO R 2 7 NCO R 2 8 NCO R 1 1 CO 2 H R 1 3 CO 2 H R 1 5 CO 2 H R 1 7 CO 2 H R 1 9 CO 2 H R 1 2 CO 2 H R 1 4 CO 2 H R 1 6 CO 2 H R 1 8 CO 2 H R 1 10 CO 2 H 10% TFA Parallel Synthesis of PPAR Ligands Pip/DMF
  • 10. PPAR Screening Data A B C D E F G H X (Acids) Y (Isocyanates) plate 1 plate 2 PPAR  PPAR  PPAR  a b c d e f g h i j k l m n o p q r s t % activation 75-100 50-75 25-50 0-25
  • 11. PPAR  Deconvolution X Y Pharmacophore PPAR  EC 50 (  M) GW 2433 e e f k n n B G B G B G — — — — — — — — 6.3 2.0 — — 1.9 0.16 6.3 0.25 7.9 1.6
  • 12. PPAR  Radioligand hPPAR  K d = 20 nM Bound (nM) 3 H-GW 2433 (nM) GW 2433 Total Specific Non-specific
  • 13.
  • 15. Resin Loading 0.63 mmole/g 100% Loading
  • 16. R 1 8 OH R 1 10 OH R 1 6 OH R 1 5 OH R 1 4 OH R 1 3 OH R 1 1 OH R 1 2 OH DIAD PPh 3 HSCH 2 COOH R 2 1 NCO R 2 2 NCO R 2 3 NCO R 2 4 NCO R 2 5 NCO R 2 6 NCO R 2 7 NCO R 2 8 NCO R 1 7 OH R 1 9 OH 10% TFA Parallel Synthesis of PPAR Ligands
  • 17. PPAR Screening Data PPAR  PPAR  GW 9578 PPAR  % activation 75-100 50-75 25-50 0-25 X (Alcohols) Y (Isocyanates)
  • 18. PPAR Profile of GW 9578 GW 9578 Fenofibric Acid 300 14 mPPAR EC 50 (  M) 0.005 18 1.5 250    Sel  GW 9578 Fenofibric Acid 1.4 >300 20 10 hPPAR EC 50 (  M) 0.05 30 1 300    Sel  GW 9578 Fenofibric Acid 2.6 >300
  • 19.
  • 20. PPAR Acknowledgements Medicinal Chemistry Peter Brown Adam Fivush Gordon Hodgson Kevin Hurley Dan Sternbach Bill Stuart Nick Tomkinson Tim Willson Tommaso Messeri Radiochemistry Itzela Correa Shimoga Prakash Structural Chemistry Paul Charifson Tom Consler Bruce Wisely Metabolic Diseases Mike Lewis Deborah Winegar William Oliver Joan Wilson Other Collaborators Jim Chapman (Univ. South Carolina) Molecular Endocrinology Steve Kliewer Jürgen Lehmann David Morris Kelli Plunket Tracey Smith-Oliver Laura Wade Molecular Biochemistry Steve Blanchard Lisa Miller Derek Parks Lisa Leesnitzer Analytical Chemistry Doug Minick

Editor's Notes

  1. By far the easiest way to encourage your colleagues to use new technologies is to demonstrate significant advances which are enabled by these new methods. Today, I will be describing some work which shows how the solid-phase synthesis of small pools of compounds has enabled the discovery of PPAR ligands.